Averoa Receives the CHMP’s Positive Opinion for Xoanacyl to Treat Chronic Kidney Disease
Shots:
- The CHMP has recommended Xoanacyl (ferric citrate complex) for chronic kidney disease, with an EU decision expected by Jun 2025, while the UK's MAA will be filed via MHRA's IRP, with decision anticipated in the coming mos.
- MAA was filed via centralized European procedure in Mar 2024 & was supported by 3 pivotal trials conducted by Akebia Therapeutics
- Averoa licensed Xoanacyl from Akebia in Dec 2022, enhancing its dossier with a re-engineered clinical package to support dual indications for EU pts. Averoa is currently seeking commercial partners for EU launch & distribution
Ref: Globenewswire | Image: Averoa
Related News:- Apellis Pharmaceuticals Reports the US FDA’s sNDA Acceptance & Priority Review of Empaveli for C3G and Primary IC-MPGN
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
